AnaptysBio unveils $100 million stock buyback initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy ANAB?
Stock Repurchase Authorization: AnaptysBio's board has approved an amended stock repurchase plan allowing the company to buy back up to $100 million of its common stock.
Current Repurchase Status: As of November 20, AnaptysBio had $6.4 million remaining under its previous $75 million repurchase plan, having already repurchased 3,443,188 shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANAB
Wall Street analysts forecast ANAB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 62.685
Low
50.00
Averages
74.13
High
140.00
Current: 62.685
Low
50.00
Averages
74.13
High
140.00
About ANAB
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AnaptysBio Q1 Earnings Report Analysis
- Disappointing Earnings: AnaptysBio reported a Q1 GAAP EPS of -$1.84, missing expectations by $1.04, indicating challenges in profitability that could undermine investor confidence.
- Collaboration Revenue Stability: Despite the overall poor financial performance, collaboration revenue reached $25.56M, down 8.0% year-over-year, yet it exceeded expectations by $6.69M, reflecting stability in the company's partnerships.
- Cash Flow Concerns: As of March 31, 2026, AnaptysBio's cash, cash equivalents, and investments totaled $286.5M, a decrease of $25.1M from $311.6M on December 31, 2025, primarily due to operating expenses, highlighting pressure on the company's financial management.
- Equity Incentive Impact: Despite the cash decline, AnaptysBio raised $14.0M through stock option exercises, somewhat alleviating cash flow pressures; however, reliance on such measures may affect long-term financial health.
See More
AnaptysBio Strengthens Leadership Team and Board
- Executive Appointments: AnaptysBio has appointed Christopher Murphy as Chief Financial Officer, leveraging his extensive experience in business development and investment banking to enhance the company's financial management and protect shareholder royalty asset value.
- Board Expansion: Owen Hughes joins the board with over 20 years of experience in royalty management and corporate development, expected to provide strategic guidance that will support AnaptysBio's long-term growth in the biotechnology sector.
- Strategic Background: Murphy previously served as CFO at Third Harmonic Bio, where he maximized company value, and played a key role in the transformation of Horizon Therapeutics PLC, showcasing his deep expertise in the biopharmaceutical industry.
- Commitment to Shareholder Value: Company executives stated that these appointments will continue AnaptysBio's strategy of protecting and returning royalty asset value, aiming to enhance shareholder confidence and drive future financial performance.
See More
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
Tesaro and AnaptysBio Litigation Update
- Court Ruling: The Delaware Chancery Court dismissed AnaptysBio's anticipatory breach of contract claim against Tesaro, a GSK subsidiary, indicating the complexity of the legal proceedings without addressing the core contractual dispute between the parties.
- Litigation Background: Tesaro initiated litigation following AnaptysBio's allegations of unmet obligations under a 2014 licensing agreement, with AnaptysBio planning to revoke Tesaro's license for dostarlimab, highlighting the tension in their collaborative relationship.
- Future Trial Schedule: AnaptysBio noted that the trial to adjudicate its contract claims and seek reversion rights for dostarlimab is set for July 14-17, 2026, which could significantly impact both parties' business strategies and market positioning.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, and the outcome of the litigation may influence its market potential and future commercialization efforts.
See More
Delaware Court Dismisses AnaptysBio's Claim Against TESARO
- Court Ruling: The Delaware Court of Chancery dismissed AnaptysBio's anticipatory breach of contract claim against TESARO, although the ruling does not address the merits of the main contractual dispute, indicating a cautious judicial stance on the allegations.
- Litigation Background: TESARO initiated this litigation following AnaptysBio's claims of non-fulfillment of the license agreement signed in March 2014, with AnaptysBio intending to revoke TESARO's license for dostarlimab, highlighting significant contractual disagreements between the parties.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S., showcasing the drug's market potential.
- Company Position: GSK and TESARO firmly believe that these allegations are entirely without merit and remain focused on pursuing a declaratory judgment against AnaptysBio in court, demonstrating the companies' strong commitment to defending their legal rights.
See More
AnaptysBio Q1 Earnings Report Analysis
- Disappointing Earnings: AnaptysBio reported a Q1 GAAP EPS of -$1.84, missing expectations by $1.04, indicating challenges in profitability that could undermine investor confidence.
- Collaboration Revenue Stability: Despite the overall poor financial performance, collaboration revenue reached $25.56M, down 8.0% year-over-year, yet it exceeded expectations by $6.69M, reflecting stability in the company's partnerships.
- Cash Flow Concerns: As of March 31, 2026, AnaptysBio's cash, cash equivalents, and investments totaled $286.5M, a decrease of $25.1M from $311.6M on December 31, 2025, primarily due to operating expenses, highlighting pressure on the company's financial management.
- Equity Incentive Impact: Despite the cash decline, AnaptysBio raised $14.0M through stock option exercises, somewhat alleviating cash flow pressures; however, reliance on such measures may affect long-term financial health.
See More
AnaptysBio Strengthens Leadership Team and Board
- Executive Appointments: AnaptysBio has appointed Christopher Murphy as Chief Financial Officer, leveraging his extensive experience in business development and investment banking to enhance the company's financial management and protect shareholder royalty asset value.
- Board Expansion: Owen Hughes joins the board with over 20 years of experience in royalty management and corporate development, expected to provide strategic guidance that will support AnaptysBio's long-term growth in the biotechnology sector.
- Strategic Background: Murphy previously served as CFO at Third Harmonic Bio, where he maximized company value, and played a key role in the transformation of Horizon Therapeutics PLC, showcasing his deep expertise in the biopharmaceutical industry.
- Commitment to Shareholder Value: Company executives stated that these appointments will continue AnaptysBio's strategy of protecting and returning royalty asset value, aiming to enhance shareholder confidence and drive future financial performance.
See More
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
Tesaro and AnaptysBio Litigation Update
- Court Ruling: The Delaware Chancery Court dismissed AnaptysBio's anticipatory breach of contract claim against Tesaro, a GSK subsidiary, indicating the complexity of the legal proceedings without addressing the core contractual dispute between the parties.
- Litigation Background: Tesaro initiated litigation following AnaptysBio's allegations of unmet obligations under a 2014 licensing agreement, with AnaptysBio planning to revoke Tesaro's license for dostarlimab, highlighting the tension in their collaborative relationship.
- Future Trial Schedule: AnaptysBio noted that the trial to adjudicate its contract claims and seek reversion rights for dostarlimab is set for July 14-17, 2026, which could significantly impact both parties' business strategies and market positioning.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, and the outcome of the litigation may influence its market potential and future commercialization efforts.
See More
Delaware Court Dismisses AnaptysBio's Claim Against TESARO
- Court Ruling: The Delaware Court of Chancery dismissed AnaptysBio's anticipatory breach of contract claim against TESARO, although the ruling does not address the merits of the main contractual dispute, indicating a cautious judicial stance on the allegations.
- Litigation Background: TESARO initiated this litigation following AnaptysBio's claims of non-fulfillment of the license agreement signed in March 2014, with AnaptysBio intending to revoke TESARO's license for dostarlimab, highlighting significant contractual disagreements between the parties.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S., showcasing the drug's market potential.
- Company Position: GSK and TESARO firmly believe that these allegations are entirely without merit and remain focused on pursuing a declaratory judgment against AnaptysBio in court, demonstrating the companies' strong commitment to defending their legal rights.
See More
